Kernal Biologics specializes in developing mRNA therapies to treat severe diseases such as cancer. Leveraging expertise from MIT, Harvard, and Big Pharma, Kernal utilizes synthetic biology and RNA design to create innovative immunotherapies. The company's distinctive approach involves programming cells to produce their own drugs, offering a promising new frontier in medical treatment.
Kernal Bio is a therapeutics company focused on engineering cells for in vivo CAR-T therapies. They are seeking a motivated scientist to lead antibody development and production. The role involves designing, developing, and producing novel antibodies, establishing internal antibody production capabilities, and collaborating with external collaborators to support preclinical and development activities.
Kernal Biologics specializes in developing mRNA therapies to treat severe diseases such as cancer. Leveraging expertise from MIT, Harvard, and Big Pharma, Kernal utilizes synthetic biology and RNA design to create innovative immunotherapies. The company's distinctive approach involves programming cells to produce their own drugs, offering a promising new frontier in medical treatment.
Biocytogen